MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation

References

• Desjardins A, Rich JN, Quinn JA, et al. Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci. 2005;10:2645–2668.
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64:6892–6899.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 2015;17:iv1–iv62.
   PubMed Web of Science ®Google Scholar
• Gallego O. Nonsurgical treatment of recurrent glioblastoma. Curr Oncol. 2015;22:e273–e281.
   PubMed Web of Science ®Google Scholar
• Nagasawa DT, Chow F, Yew A, et al. Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am. 2012;23:307–322. ix.
   PubMed Web of Science ®Google Scholar
• Kartner N, Ling V. Multidrug resistance in cancer. Sci Am. 1989;260:44–51.
   PubMed Web of Science ®Google Scholar
• Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer - mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11:265–283.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061–1068.
   PubMed Web of Science ®Google Scholar
• Sarkaria JN, Kitange GJ, James CD, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900–2908.
   PubMed Web of Science ®Google Scholar
• Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3:198–210.
   PubMed Web of Science ®Google Scholar
• Bobola MS, Tseng SH, Blank A , et al. Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res. 1996;2:735–741.
   PubMed Web of Science ®Google Scholar
• Newcomb EW, Bhalla SK, Parrish CL, et al. bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol. 1997;94:369–375.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–310.
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49–53.
   PubMed Web of Science ®Google Scholar
• Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413–431.
   PubMed Web of Science ®Google Scholar
• Lin J, Chen J, Elenbaas B, et al. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 1994;8:1235–1246.
   PubMed Web of Science ®Google Scholar
• Kobet E, Zeng X, Zhu Y, et al. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci USA. 2000;97:12547–12552.
   PubMed Web of Science ®Google Scholar
• Haupt Y, Maya R, Kazaz A, et al. MDM2 promotes the rapid degradation of p53. Nature. 1997;387:296–299.
   PubMed Web of Science ®Google Scholar
• Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer. 2003;3:102–109.
   PubMed Web of Science ®Google Scholar
• Momand J, Jung D, Wilczynski S, et al. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26:3453–3459.
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–848.
   PubMed Web of Science ®Google Scholar
• Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA. 2006;103:1888–1893.
   PubMed Web of Science ®Google Scholar
• Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 2006;107:4109–4114.
   PubMed Web of Science ®Google Scholar
• Drakos E, Thomaides A, Medeiros LJ, et al. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res. 2007;13:3380–3387.
   PubMed Web of Science ®Google Scholar
• Ohnstad HO, Paulsen EB Noordhuis P, et al. MDM2 antagonist nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines. BMC Cancer. 2011;11:211–211.
   PubMed Web of Science ®Google Scholar
• Das M, Dilnawaz F, Sahoo SK. Targeted nutlin-3A loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy. Nanomedicine (Lond). 2011;6:489–507.
   PubMed Web of Science ®Google Scholar
• Voltan R, Secchiero P, Ruozi B, et al. Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts. Clin Cancer Res. 2013;19:3871–3880.
   PubMed Web of Science ®Google Scholar
• Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009;9:338–350.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134.
   PubMed Web of Science ®Google Scholar
• Rittierodt M, Harada K. Repetitive doxorubicin treatment of glioblastoma enhances the PGP expression–a special role for endothelial cells. Exp Toxicol Pathol. 2003;55:39–44.
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Lukyanov AN, Gao Z, et al. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA. 2003;100:6039–6044.
   PubMed Web of Science ®Google Scholar
• Sarisozen C, Dhokai S, Tsikudo EG, et al. Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: in vitro evaluation on 2D and 3D tumor models. Eur J Pharm Biopharm. 2016;108:54–67.
   PubMed Web of Science ®Google Scholar
• Dabholkar RD, Sawant RM, Mongayt DA, et al. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm. 2006;315:148–157.
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Levchenko TS, Lukyanov AN, et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta. 2001;1511:397–411.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–446.
   PubMed Web of Science ®Google Scholar
• Burgess A, Chia KM, Haupt S, et al. Clinical overview of MDM2/X-targeted therapies. Front Oncol. 2016;6:7.
   PubMed Web of Science ®Google Scholar
• Patton JT, Mayo LD, Singhi AD, et al. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to nutlin-3. Cancer Res. 2006;66:3169–3176.
   PubMed Web of Science ®Google Scholar
• van Leeuwen IM, Higgins M, Campbell J, et al. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle. 2011;10:1590–1598.
   PubMed Web of Science ®Google Scholar
• Abouzeid AH, Patel NR, Sarisozen C, et al. Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells. Pharm Res. 2014;31:1938–1945.
   PubMed Web of Science ®Google Scholar
• Sawant RR, Jhaveri AM, Koshkaryev A, et al. The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy. J Drug Target. 2013;21:630–638.
   PubMed Web of Science ®Google Scholar
• Deben C, Wouters A, Op de Beeck K, et al. The MDM2-inhibitor nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. Oncotarget. 2015;6:22666–22679.
   PubMedGoogle Scholar
• Allen C, Maysinger D, Eisenberg A. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf B Biointerfaces. 1999;16:3–27.
   Web of Science ®Google Scholar
• Sarisozen C, Abouzeid AH, Torchilin VP. The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors. Eur J Pharm Biopharm. 2014;88:539–550.
   PubMed Web of Science ®Google Scholar
• Al-Abd AM, Aljehani ZK, Gazzaz RW, et al. Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors. J Control Release. 2015;219:269–277.
   PubMed Web of Science ®Google Scholar